Inhaled unfractionated heparin improves abnormalities of alveolar coagulation, fibrinolysis and inflammation in endotoxemia-induced lung injury rats

Chinese Medical Journal

Volumn 126, Issue 2, 2013, Pages 318-324

  Wang, Zong Yu ^a   Wu, Sheng Nan ^b   Zhu, Zhao Zhong ^c   Yang, Ba Xian ^d   Zhu, Xi ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

^c Case Western Reserve University   (United States)

^d PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Acute lung injury; Administration by inhalation; Coagulation; Endotoxemia; Heparin

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR; HEPARIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MYELOPEROXIDASE; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ANTITHROMBIN COMPLEX; TUMOR NECROSIS FACTOR ALPHA; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; ENDOTOXEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRIN DEPOSITION; FIBRINOLYSIS; GENETIC HETEROGENEITY; HISTOLOGY; INFLAMMATION; LUNG INJURY; LUNG LAVAGE; MALE; NONHUMAN; PATHOLOGY; PNEUMONIA; PROPHYLAXIS; RAT;

ACUTE LUNG INJURY; ADMINISTRATION, INHALATION; ANIMALS; BLOOD COAGULATION; ENDOTOXEMIA; FIBRINOLYSIS; HEPARIN; INFLAMMATION; LUNG; MALE; RATS; RATS, WISTAR;

EID: 84872744517     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20121412     Document Type: Article

References (30)

1. Hudson LD, Milberg JA, Anardi D, Maunder RJ. Clinical risks for development of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1995; 151: 293-301.
2. Knoebl P. Blood coagulation disorders in septic patients. Wien Med Wochenschr 2010; 160: 129-138.
3. Wygrecka M, Jablonska E, Guenther A, Preissner KT, Markart P. Current view on alveolar coagulation and fibrinolysis in acute inflammatory and chronic interstitial lung diseases. Thromb Haemost 2008; 99: 494-501.
4. Gunther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, et al. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161: 454-462.
5. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010; 38(2 Suppl): S26-S34.
6. Esmon CT. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J Exp Med 2002; 196: 561-564.
7. Liu KD, Levitt J, Zhuo H, Kallet RH, Brady S, Steingrub J, et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med 2008; 178: 618-623.
8. Abraham E, Reinhart K, Svoboda P, Seibert A, Olthoff D, Dal Nogare A, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001; 29: 2081-2089.
9. Zarychanski R, Doucette S, Fergusson D, Roberts D, Houston DS, Sharma S, et al. Early intravenous unfractionated heparin and mortality in septic shock. Crit Care Med 2008; 36: 2973-2979.
10. Murakami K, McGuire R, Cox RA, Jodoin JM, Bjertnaes LJ, Katahira J, et al. Heparin nebulization attenuates acute lung injury in sepsis following smoke inhalation in sheep. Shock 2002; 18: 236-241.
11. Bendstrup KE, Gram J, Jensen JI. Effect of inhaled heparin on lung function and coagulation in healthy volunteers. Eur Respir J 2002; 19: 606-610.
12. Smith KM, Mrozek JD, Simonton SC, Bing DR, Meyers PA, Connett JE, et al. Prolonged partial liquid ventilation using conventional and high-frequency ventilatory techniques: gas exchange and lung pathology in an animal model of respiratory distress syndrome. Crit Care Med 1997; 25: 1888-1897.
13. Olson ST, Bjork I, Sheffer R, Craig PA, Shore JD, Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992; 267: 12528-12538.
14. Deguchi K, Noguchi M, Yuwasaki E, Endou T, Deguchi A, Wada H, et al. Dynamic fluctuations in blood of thrombin/antithrombin III complex (TAT). Am J Hematol 1991; 38: 86-89.
15. Choi G, Vlaar AP, Schouten M, Van't VC, van der Poll T, Levi M, et al. Natural anticoagulants limit lipopolysaccharide-induced pulmonary coagulation but not inflammation. Eur Respir J 2007; 30: 423-428.
16. Dixon B, Schultz MJ, Hofstra JJ, Campbell DJ, Santamaria JD. Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury. Crit Care 2010; 14: 445.
17. Hofstra JJ, Vlaar AP, Cornet AD, Dixon B, Roelofs JJ, Choi G, et al. Nebulized anticoagulants limit pulmonary coagulopathy, but not inflammation, in a model of experimental lung injury. J Aerosol Med Pulm Drug Deliv 2010; 23: 105-111.
18. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 2006; 32 Suppl 1: 49-60.
19. Weiler H. Regulation of inflammation by the protein C system. Crit Care Med 2010; 38(2 Suppl): S18-S25.
20. Idell S, James KK, Gillies C, Fair DS, Thrall RS. Abnormalities of pathways of fibrin turnover in lung lavage of rats with oleic acid and bleomycin-induced lung injury support alveolar fibrin deposition. Am J Pathol 1989; 135: 387-399.
21. Wygrecka M, Markart P, Ruppert C, Kuchenbuch T, Fink L, Bohle RM, et al. Compartment-and cell-specific expression of coagulation and fibrinolysis factors in the murine lung undergoing inhalational versus intravenous endotoxin application. Thromb Haemost 2004; 92: 529-540.
22. Wygrecka M, Markart P, Ruppert C, Petri K, Preissner KT, Seeger W, et al. Cellular origin of pro-coagulant and (anti)-fibrinolytic factors in bleomycin-injured lungs. Eur Respir J 2007; 29: 1105-1114.
23. Li LF, Huang CC, Lin HC, Tsai YH, Quinn DA, Liao SK. Unfractionated heparin and enoxaparin reduce high-stretch ventilation augmented lung injury: a prospective, controlled animal experiment. Crit Care 2009; 13: R108.
24. van der Poll T, van Deventer SJ. Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am 1999; 13: 413-426.
25. Szaba FM, Smiley ST. Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood 2002; 99: 1053-1059.
26. Hochart H, Jenkins PV, Smith OP, White B. Low-molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-kappaB in LPS-stimulated human monocytes. Br J Haematol 2006; 133: 62-67.
27. Hochart H, Jenkins PV, Preston RJ, Smith OP, White B, O'Donnell J. Concentration-dependent roles for heparin in modifying lipopolysaccharide-induced activation of mononuclear cells in whole blood. Thromb Haemost 2008; 99: 570-575.
28. Knapp S, Leemans JC, Florquin S, Branger J, Maris NA, Pater J, et al. Alveolar macrophages have a protective antiinflammatory role during murine pneumococcal pneumonia. Am J Respir Crit Care Med 2003; 167: 171-179.
29. Bendstrup KE, Chambers CB, Jensen JI, Newhouse MT. Lung deposition and clearance of inhaled (99m)Tc-heparin in healthy volunteers. Am J Respir Crit Care Med 1999; 160: 1653-1658.
30. Karrasch S, Eder G, Bolle I, Tsuda A, Schulz H. Breath-by-breath measurement of particle deposition in the lung of spontaneously breathing rats. J Appl Physiol 2009; 107: 1293-1299.